Prediabetes and cardiovascular risk in hypertensive patients

Current Hypertension Reports

Volumn 8, Issue 2, 2006, Pages 97-100

  Segura, Julian ^a   Roldän, Cecilia ^b   García Donaire, Jose A ^b   Ruilope, Luis M ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; GLUCOSE; NATEGLINIDE; RAMIPRIL; ROSIGLITAZONE; SIBUTRAMINE; VALSARTAN;

ACUTE HEART INFARCTION; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETOGENESIS; DISEASE ASSOCIATION; EDITORIAL; ETHNOLOGY; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK POPULATION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

EID: 33744491284     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-006-0001-3     Document Type: Editorial

References (45)

1. Narayan KM, Imperatore G, Benjamin SM, Engelgau MM: Targeting people with pre-diabetes. BMJ 2002, 325:403-404.
2. de Vegt F, Dekker JM, Jager A, et al.: Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA 2001, 285:2109-2113.
3. Lindholm LH, Ibsen H, Borch-Johnsen K, et al.: Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002, 20:1879-1886.
4. American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases: The prevention or delay of type 2 diabetes. Diabetes Care 2002, 25:1-8.
5. Genuth S, Alberti KG, Bennett P, et al.: Follow-up report on the diagnosis of diabetes mellitus. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003, 26:3160-3167.
6. D'Agostino RB Jr, Hamman RF, Karter AJ, et al.: Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care 2004, 27:2234-2240.
7. Benjamin SM, Valdez R, Geiss LS, et al.: Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention. Diabetes Care 2003, 26:645-649.
8. García Puig J, Ruilope LM, Luque Otero M, Bobadilla JF: Prevalence of carbohydrate metabolic alterations in hospital based hypertension units in Spain: The AVANT study (abstract). J Hypertens 2004, 22(Suppl 1):S97.
9. Björnholt J, Erikssen G, Aaser E, et al.: Fasting blood glucose: an underestimated risk factor for cardiovascular death: results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care 1999, 22:45-49.
10. DECODE Study Group, European Diabetes Epidemiology Group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003, 26:688-696.
11. DECODE Study Group, European Diabetes Epidemiology Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999, 354:617-621.
12. Meigs JB, Nathan DM, Wilson PW, et al.: Metabolic risk factors worsen continuously across the spectrum of non-diabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med 1998, 128:524-533.
13. Lim SC, Tai ES, Tan BY, et al.: Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report. Diabetes Care 2000, 23:278-282.
14. Hanefeld M, Koehler C, Fuecker K, et al.: Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study. Diabetes Care 2003, 26:868-874.
15. Bartnik M, Malmberg K, Norhammar A, et al.: Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004, 25:1990-1997.
16. Norhammar A, Tenerz A, Nilsson G, et al.: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002, 359:2140-2144.
17. Bartnik M, Ryden L, Ferrari R, et al.: The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004, 25:1880-1890.
18. Aguilar D, Solomon SD, Kober L, et al.: Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the Valsartan in Acute Myocardial Infarction (VALIANT) trial. Circulation 2004, 110:1572-1578.
19. Kernan WN, Viscoli CM, Inzucchi SE, et al.: Prevalence of abnormal glucose tolerance following a transient ischemic attack or ischemic stroke. Arch Intern Med 2005, 165:227-233.
20. Cohen HW, Hailpern SM, Alderman MH: Glucose-cholesterol interaction magnifies coronary heart disease risk for hypertensive patients. Hypertension 2004, 43:983-987.
21. Hu FB, Stampfer MJ, Haffner SM. et al.: Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002, 25:1129-1134.
22. Pepine CJ, Cooper-DeHoff RM: Cardiovascular therapies and risk for development of diabetes. J Am Coll Cardiol 2004, 44:509-512.
23. Diabetes Prevention Program Research Group: Strategies to identify adults at high risk for type 2 diabetes: the Diabetes Prevention Program. Diabetes Care 2005, 28:138-144.
24. Schmidt MI, Duncan BB, Bang H, et al.: Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities Study. Diabetes Care 2005, 28:2013-2018.
25. Reaven G: Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002, 106:286-288.
26. Ford ES: Risk for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005, 28:1769-1778.
27. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
28. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
29. Ford ES, Giles WH, Mokdad AH: Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care 2004, 27:2444-2449.
30. Banegas JR, Ruilope LM: Epidemic of metabolic diseases. A warning call. Med Clin (Barc) 2003, 120:99-100.
31. Segura J, Campo C, Roldan C, et al.: Hypertensive renal damage in metabolic syndrome is associated with glucose metabolism disturbances. J Am Soc Nephrol 2004, 15(Suppl1):S37-S42.
32. Bruno G, Merletti F, Biggeri A, et al.: Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2004, 27:2689-2694.
33. Alberti KGH, Zimmet P, Shaw J: The metabolic syndrome - a new worldwide definition. For the IDF Epidemiology Task Force Consensus Group. Lancet 2005, 366:1059-1062.
34. Messerli FH, Grossman E, Leonetti G: Antihypertensive therapy and new onset diabetes. J Hypertens 2004, 22:1845-1847.
35. Pepine CJ, Cooper-DeHoff RM: Cardiovascular therapies and risk for development of diabetes. J Am Coll Cardiol 2004, 44:509-512.
36. Opie LH, Schall R: Old antihypertensive and new diabetes. J Hypertens 2004, 22:1453-1458.
37. Mancia G, Grassi G, Zanchetti A: New-onset diabetes and antihypertensive drugs. J Hypertens 2006, 24:3-10.
38. Cranston WI, Juel-Jensen BE, Semmence AM, et al.: Effects of oral diuretics on raised arterial pressure. Lancet 1963, 186:966-970.
39. Lewis PJ, Kohner EM, Petrie A, Dollery CT. Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment. Lancet 1976, 1:564-566.
40. Murphy MB, Lewis PJ, Kohner E, et al.: Glucose intolerance in hypertensive patients treated with diuretics, a fourteen-year follow-up. Lancet 1982, 2:1293-1295.
41. Medical Research Council: Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of the Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet 1981, 2:543-549.
42. Zanchetti A, Ruilope LM: Antihypertensive treatment in patients with type 2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002, 20:2099-2110.
43. Alderman MH, Cohen H, Madhavan S: Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999, 33:1130-1134.
44. Eberly LE, Cohen JD, Prineas R, Yang L: Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience. Intervention Trial Research group. Diabetes Care 2003, 26:848-854.
45. Verdecchia P, Reboldi G, Angeli F, et al.: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004, 43:963-969.